Antisoma slips back to red ahead of expected Sportingbet deal

Cancer drug developer Antisoma saw a return to the red at its half-year report statement, reporting a 30,000 pound loss after tax.

Cancer drug developer Antisoma saw a return to the red at its half-year report statement, reporting a 30,000 pound loss after tax.

This compares to profits of £424,000 for the full year, reported last October, when the group restructured its activities to become an investment company.

Antisoma made its first major deal as an investment company in the most recent trading period, via an agreement to subscribe to up to £4.0m in new shares proposed for issuance by GVC Holdings. This is in connection with GVC's recommended offer, alongside William Hill, for Sportingbet.

Confirmation on the size of Antisoma's holding in GVC is expected on March 31st.

In the half year to December 31st, Antisoma continued to cut costs, and is now sitting on £12.88m in cash, and short term deposit balances of £9.48m.

Antisoma previously focused on cancer therapy development, but suffered a blow in early 2011 when both its drugs failed in final-stage trials. The group then stopped all its drugs development programmes in an effort to save cash, ahead of the restructuring.

Chairman Michael Bretherton was cautiously optimistic in his outlook for the company, pointing to the troubles in the general economy.

Still, he believes Antisoma's strong cash position and low cost base are encouraging: "This places the company in a good position to exploit opportunities as they emerge in the current volatile economic environment. We will therefore continue to maintain a highly selective investment approach."

JF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Bitcoin: fool’s gold or the new gold?
Bitcoin

Bitcoin: fool’s gold or the new gold?

With bitcoin hitting new highs last week, and close to becoming a mainstream investment, is it really gold for the 21st century?
15 Jan 2021
Forget austerity – governments and central banks have no intention of cutting back
Global Economy

Forget austerity – governments and central banks have no intention of cutting back

Once the pandemic is over will we return to an era of austerity to pay for all the stimulus? Not likely, says John Stepek. The money will continue to …
15 Jan 2021
The MoneyWeek Podcast: bitcoin special
Bitcoin

The MoneyWeek Podcast: bitcoin special

Merryn talks to bitcoin experts Dominic Frisby and Charlie Morris to get the lowdown on the cryptocurrency to find out why it's such a huge global phe…
15 Jan 2021
Free 6 issue trial then continue to